Affiliation:
1. Center for Women’s Reproductive Health
2. Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Alabama at Birmingham, Birmingham, Alabama
Abstract
We describe the evolution of treatment recommendations for chronic hypertension (CHTN) in pregnancy, the CHTN and pregnancy (CHAP) trial, and its impact on obstetric practice. The US multicenter CHAP trial showed that antihypertensive treatment for mild CHTN in pregnancy [blood pressures (BP)<160/105 mm Hg] to goal<140/90 mm Hg, primarily with labetalol or nifedipine compared with no treatment unless BP were severe reduced the composite risk of superimposed severe preeclampsia, indicated preterm birth <35 weeks, placental abruption, and fetal/neonatal death. As a result of this trial, professional societies in the United States recommended treatment of patients with CHTN in pregnancy to BP goal<140/90 mm Hg.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference21 articles.
1. Changes in the prevalence of chronic hypertension in pregnancy, United States, 1970 to 2010;Ananth;Hypertension,2019
2. Obesity in pregnancy;Creanga;N Engl J Med,2022
3. ACOG Practice Bulletin No. 203: chronic hypertension in pregnancy;Vidaeff;Obstetrics and gynecology,2019
4. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Whelton;Hypertension,2018
5. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association;Garovic;Hypertension,2022